Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab plus chemotherapy versus cetuximab plus chemotherapy in first-line left-sided RAS/BRAF wild-type metastatic colorectal cancer
2024-513852-13-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial in colorectal cancer (CRC) comparing Amivantamab + chemotherapy with Cetuximab + chemotherapy (2 arms). Primary endpoint: Progression-free survival. Planned start Jan 2025; status: authorised.
02
Drugs
amivantamabcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-513852-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513852-13-00.